Special Issue "Pre-clinical Pharmacology and Pharmacokinetics in Oral Drug Delivery"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 10 July 2021.

Special Issue Editors

Dr. Fiona McCartney
E-Mail Website
Guest Editor
UCD School of Veterinary Medicine and UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
Interests: oral drug delivery; permeation enhancers; intestine; nanoparticles; bioactive compounds; peptides
Dr. John Gleeson
E-Mail Website
Guest Editor
Biopharmaceutics - Pharmaceutical Sciences, Merck & Co., Rahway, NJ 07065, USA
Interests: oral drug delivery; intestinal models; IVIVC; permeation enhancers; biopharmaceuticals

Special Issue Information

Dear Colleagues,

Oral drug delivery, while being the patient-preferred route of delivery, is challenging because of chemical (pH and enzymes) and physical (mucus and epithelia) barriers. A number of strategies have been investigated in order to overcome these barriers, such as modifying drugs to improve stability, the use of permeation enhancers to improve intestinal absorption, and nanoparticles and novel drug delivery systems to improve overall bioavailability. Although current preclinical assessment is heavily dependent on rodent models, there is a need to develop novel in vitro and ex vivo models that better predict human in vivo pharmacokinetics, such as intestinal organoid and microfluidic devices.

This Special Issue will focus on novel approaches to improve the oral bioavailability of drugs as well as strategies to increase the intestinal permeability of drugs. Novel pre-clinical models of the intestine that can improve the in vitro in vivo correlation (IVIVC) are of particular interest in this Special Issue, as are physiologically-based pharmacokinetic (PBPK) models of the intestine or oral drug delivery in preclinical species.

Dr. Fiona McCartney
Dr. John Gleeson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oral drug delivery
  • oral bioavailability
  • in vitro in vivo correlation (IVIVC)
  • physiologically-based pharmacokinetic modelling (PBPK)
  • intestinal permeability
  • intestinal absorption
  • drug transporters
  • tight junctions

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Effect of Curcumin Nanoemulsions Stabilized with MAG and DAG-MCFAs in a Fructose-Induced Hepatic Steatosis Rat Model
Pharmaceutics 2021, 13(4), 509; https://doi.org/10.3390/pharmaceutics13040509 - 08 Apr 2021
Viewed by 231
Abstract
Current changes in diet, characterized by an increase in the intake of sweetened beverages, are heavily related to metabolic disorders such as non-alcoholic fatty liver. This condition can produce simple steatosis and, in worse cases, potentially result in steatohepatitis, fibrosis, and cirrhosis, comparable [...] Read more.
Current changes in diet, characterized by an increase in the intake of sweetened beverages, are heavily related to metabolic disorders such as non-alcoholic fatty liver. This condition can produce simple steatosis and, in worse cases, potentially result in steatohepatitis, fibrosis, and cirrhosis, comparable to the damage caused by the consumption of more or less 20–30 g of alcohol per day. The main objective of this research was to evaluate the effect of curcumin (Curcuma longa) nanoemulsions, using mono- and diacylglycerides medium chain fatty acids as stabilizers in an in vivo hepatic steatosis rat model. Pathology was induced by providing 30% fructose intake in the drinking water. Globule sizes under 200 nm that were stable for 4 weeks were obtained; curcumin encapsulated in the nanoemulsion was >70%. The results revealed an improvement regarding body and liver weight in the animals treated with curcumin nanoemulsions. A decrease in total cholesterol, LDL, AST/ALT, and HDL in serum was observed; however, no apparent improvement regarding serum glucose or triacylglycerides values was noted. Histological analysis showed a significant decrease in the extent of steatosis, inflammation, and brown adipose tissue in the treated animals. Full article
(This article belongs to the Special Issue Pre-clinical Pharmacology and Pharmacokinetics in Oral Drug Delivery)
Show Figures

Graphical abstract

Back to TopTop